Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case

By Elias Schisgall

Halozyme was granted a preliminary injunction that would prevent Merck & Co. from distributing a formulation of Keytruda in Germany as part of a patent-infringement dispute over the cancer treatment.

The Munich Regional Court ruled Thursday there was imminent infringement for Merck & Co.'s Keytruda SC in Germany related to Halozyme's MDASE patents in Europe, the San Diego company said.

Merck & Co. didn't immediately respond to a request for comment.

The ruling applies only to the subcutaneous formulation of the Rahway, N.J., company's treatment, rather than the intravenous formulation, which Halozyme said isn't covered by its own patents.

Merck separately launched nullity proceedings against Halozyme's patent in German Federal Patent Court in August.

Halozyme also has brought legal action against Merck & Co. in New Jersey federal courts to block the company from distributing Keytruda SC in the U.S.

Write to Elias Schisgall at [e-mail]

Corrections & Amplifications

This article was corrected at 3:27 p.m. ET because it incorrectly said Halozyme had launched nullity proceedings against Merck. Merck & Co. launched nullity proceedings against Halozyme's patent in German Federal Patent Court in August.

(END) Dow Jones Newswires

12-04-25 1423ET